Inferra AI / Company / NVAX
Novavax Inc.
NVAX · Health Care
Last earnings Aug 6, 2026
Key results
Operational Highlights Total revenuequarter
$239 million
htm EX-99.1 Document Press Release Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights Total revenue of $239 million in the second quarter of 2025 Received FDA BLA approval for Nuvaxovid , the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Total revenuequarter
$239 million
Second Quarter 2025 Financial Results Total revenue for the second quarter of 2025 was $239 million, compared to $415 million in the same period in 2024.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Other revenuequarter
$229 million
Licensing, Royalties and Other Revenue of $229 million in the second quarter of 2025 includes a $175 million milestone earned related to the Nuvaxovid BLA approval.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Net incomequarter
$107 million
Net income for the second quarter of 2025 was $107 million, compared to net income of $162 million in the same period in 2024.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Nuvaxovid Product revenuequarter
$610 million
Nuvaxovid Product Sales of $610 million include $603 million in revenue recognized in the first quarter of 2025 from the termination of the Canada and New Zealand Advance Purchase Agreements, plus sales by Novavax in the U.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Adjusted Licensing, Royalties and Other Revenue includes $225 million in U.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
AI analysis
Q2 2025 · reported Aug 6, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Segment mix
Business-unit revenue, as stated
Segment revenue figures as stated in the event record.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Operational Highlights Total revenue | $239 million | — | — |
| Total revenue | $239 million | — | $415 million |
| Other revenue | $229 million | — | — |
| Net income | $107 million | — | — |
| Nuvaxovid Product revenue | $610 million | — | — |
Guidance · company-stated
Direction: Initiated
“to Sanofi for the 2025-2026 COVID-19 vaccination season COVID-19-Influenza-Combination and stand-alone influenza vaccine candidates showed robust immune responses in initial cohort of a Phase 3 trial with new T-cell response data in both Novavax vaccine candidates numerically higher than in the comparator Fluzone HD arm Updated Full Year 2025 Revenue Framework and Financial Guidance Company to host conference call today at 8 30 a.”
Classified from the release's primary full-year outlook statement.
Capital allocation
As of December 31, 2025, marketable securities were comprised of $ 220.3 million of treasury securities, of which $ 162.4 million mature in 2026 and $ 57.9 million mature in 2027; $ 260.2 million of corporate debt securities, of which $ 250.9 million mature in 2026 and $ 9.3 million mature in 2027; and $ 14.0 million in agency securities that mature in 2027.
(3) Classified as Long-term debt as of June 30, 2026 and December 31, 2025, respectively, on the consolidated balance sheets.
Event summary
Novavax Inc. — Earnings release (2025-08-06)
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Initiated
Revenue — Initiated (“initial”)
“to Sanofi for the 2025-2026 COVID-19 vaccination season COVID-19-Influenza-Combination and stand-alone influenza vaccine candidates showed robust immune responses in initial cohort of a Phase 3 trial with new T-cell response data in both Novavax vaccine candidates numerically higher than in the comparator Fluzone HD arm Updated Full Year 2025 Revenue Framework and Financial Guidance Company to host conference call today at 8 30 a.”
Classified from the release's primary full-year outlook statement.
Capital allocation
As of December 31, 2025, marketable securities were comprised of $ 220.3 million of treasury securities, of which $ 162.4 million mature in 2026 and $ 57.9 million mature in 2027; $ 260.2 million of corporate debt securities, of which $ 250.9 million mature in 2026 and $ 9.3 million mature in 2027; and $ 14.0 million in agency securities that mature in 2027.
SEC original ↗Novavax Inc. — 10-Q Quarterly report10-QAug 6, 2026
(3) Classified as Long-term debt as of June 30, 2026 and December 31, 2025, respectively, on the consolidated balance sheets.
SEC original ↗Novavax Inc. — 10-Q Quarterly report10-QAug 6, 2026
During the six months ended June 30, 2026, the Company entered into a Credit, Security, and Guaranty Agreement (the Credit Agreement ) with MidCap Financial Trust, which provides for a senior secured term loan facility of up to $ 330.0 million, of which $ 50.0 million was funded at closing (see Note 11).
SEC original ↗Novavax Inc. — 10-Q Quarterly report10-QAug 6, 2026
Since the term loan was issued at market terms and bears interest at a variable rate based on the one-month Secured Overnight Financing Rate plus 5.00 %, its funded amount of $ 50.0 million approximates its fair value as of June 30, 2026.
SEC original ↗Novavax Inc. — 10-Q Quarterly report10-QAug 6, 2026
Borrowings under the Credit Agreement bear interest, payable monthly in arrears, at a rate per annum equal to the one-month Secured Overnight Financing Rate ( Term SOFR ) plus 5.00 %, subject to a Term SOFR floor of 2.00 %.
SEC original ↗Novavax Inc. — 10-Q Quarterly report10-QAug 6, 2026
Any repayment of the term loan is subject to a 2.75 % exit fee payable on the maturity date or earlier date through voluntary or mandatory prepayment, which is being accrued for over the term of the Credit Agreement.
SEC original ↗Novavax Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
This quarter we continued to progress our growth strategy with key achievements including BLA approval for our COVID-19 vaccine, positive data from our COVID-19-Influenza-Combination and stand-alone influenza programs, advancement of our early-stage pipeline, and progression of our partnership strategy, said John C.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Second Quarter 2025 and Recent Highlights Strategic Priority #1 Sanofi Partnership In May 2025, the U.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Strategic Priority #2 Enhance Existing Partnerships and Leverage our Technology Platform and Pipeline to Forge Additional Partnerships In June 2025, the company reported initial cohort data for the Phase 3 trial for its COVID-19-Influenza - Combination (CIC) and stand-alone seasonal influenza vaccine candidates, showing robust immune responses for both candidates.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Strategic Priority #3 Advance our Technology Platform and Early-stage Pipeline In July 2025, the Company announced preclinical data demonstrating that Novavax s H5N1 avian pandemic influenza vaccine candidate induced robust immune responses by either single or two-dose intranasal or intramuscular administration in primed non-human primates.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
The Company s growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via R D innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Risks & headwinds
(Nasdaq NVAX) tackles some of the world s most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
com , for a discussion of these and other risks and uncertainties.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Our business is subject to substantial risks and uncertainties, including those referenced above.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
SEC original ↗Novavax Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025
Legal Proceedings 42 Item 1A.
SEC original ↗Novavax Inc. — 10-Q Quarterly report10-QAug 6, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
30 documents- Q2 2026
- 10-QNVAX
Aug 6, 2026
- 8-KNVAX
Aug 6, 2026
- Q1 2026
- 8-KNVAX
Jun 23, 2026
- 10-QNVAX
May 6, 2026
- 8-KNVAX
May 6, 2026
- Q4 2025
- 10-KNVAX
Feb 26, 2026
- 8-KNVAX
Feb 26, 2026
- 8-KNVAX
Jan 20, 2026
- 8-KNVAX
Jan 12, 2026
- Q3 2025
- 10-QNVAX
Nov 6, 2025
- 8-KNVAX
Nov 6, 2025
- 8-KNVAX
Nov 4, 2025
- 8-KNVAX
Oct 22, 2025
- 8-KNVAX
Oct 7, 2025
- Q2 2025
- 8-KNVAX
Aug 27, 2025
- 8-KNVAX
Aug 27, 2025
- 8-KNVAX
Aug 21, 2025
- 10-QNVAX
Aug 6, 2025
- 8-KNVAX
Aug 6, 2025
- Q1 2025
- 8-KNVAX
Jun 24, 2025
- 8-KNVAX
Jun 11, 2025
- 8-KNVAX
May 27, 2025
- 8-KNVAX
May 19, 2025
- 10-QNVAX
May 8, 2025
- 8-KNVAX
May 8, 2025
- 8-KNVAX
May 5, 2025
- 8-KNVAX
Apr 29, 2025
- 8-KNVAX
Apr 23, 2025
- 8-KNVAX
Apr 2, 2025
- Q4 2024
- 8-KNVAX
Mar 11, 2025
Earnings releases
7 documentsPresentations
0 documentsNo presentations for Novavax Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Novavax Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.